TW591030B
(en)
|
1997-03-10 |
2004-06-11 |
Janssen Pharmaceutica Nv |
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
|
ES2216535T3
(es)
*
|
1998-06-16 |
2004-10-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Derivados de imidazolilo.
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
AU762423B2
(en)
|
1998-07-06 |
2003-06-26 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties
|
CN1170538C
(zh)
*
|
1998-07-06 |
2004-10-13 |
詹森药业有限公司 |
供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
|
EP1107962B1
(en)
*
|
1998-08-27 |
2005-02-23 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
US6284755B1
(en)
|
1998-12-08 |
2001-09-04 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
DE69907964T2
(de)
|
1998-12-23 |
2004-02-19 |
Janssen Pharmaceutica N.V. |
1,2-annelierte chinolinderivate
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(en)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazolyl derivatives
|
DE60038498T2
(de)
|
1999-11-15 |
2009-05-07 |
Janssen Pharmaceutica N.V. |
Triazole als Farnesyltransferaseinhibitoren
|
ES2212971T3
(es)
|
1999-11-30 |
2004-08-16 |
Pfizer Products Inc. |
Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
|
KR20010077400A
(ko)
*
|
2000-02-02 |
2001-08-17 |
성재갑 |
에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제
|
DK1255537T3
(da)
*
|
2000-02-04 |
2006-08-21 |
Janssen Pharmaceutica Nv |
Farnesylproteintransferasehæmmere til behandling af brystcancer
|
US6838467B2
(en)
|
2000-02-24 |
2005-01-04 |
Janssen Pharmaceutica N. V. |
Dosing regimen
|
AU2001254672A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
EP1267871A2
(en)
*
|
2000-02-29 |
2003-01-02 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
US20030212008A1
(en)
*
|
2000-02-29 |
2003-11-13 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
WO2001064199A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with taxane compounds
|
CA2397253A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
US20030186925A1
(en)
*
|
2000-02-29 |
2003-10-02 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
|
WO2001064194A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with camptothecin compounds
|
WO2001064218A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations
|
CA2397446A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
|
US20030027808A1
(en)
*
|
2000-02-29 |
2003-02-06 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with platinum compounds
|
AU2001242434A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with vinca alkaloids
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
ATE318816T1
(de)
*
|
2000-09-21 |
2006-03-15 |
Takeda Pharmaceutical |
Verfahren zur produktion eines trizyklischen kondensierten heterozyklischen derivats
|
EP1322636A1
(en)
|
2000-09-25 |
2003-07-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
|
AU2001293835A1
(en)
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
US7196094B2
(en)
|
2000-09-25 |
2007-03-27 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
|
WO2002024682A1
(en)
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
ES2328225T3
(es)
|
2000-11-21 |
2009-11-11 |
Janssen Pharmaceutica Nv |
Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
|
JP4231691B2
(ja)
*
|
2000-11-28 |
2009-03-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
|
JP4351445B2
(ja)
|
2000-12-27 |
2009-10-28 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する4−置換−キノリンおよびキナゾリン誘導体
|
US20040110769A1
(en)
*
|
2001-02-15 |
2004-06-10 |
End David William |
Farnesyl protein transferase inhibitor combinations with antiestrogen agents
|
SI1373255T1
(no)
|
2001-03-12 |
2005-08-31 |
Janssen Pharmaceutica Nv |
|
ES2323265T3
(es)
*
|
2001-12-19 |
2009-07-10 |
Janssen Pharmaceutica Nv |
Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
|
US7241777B2
(en)
|
2002-03-22 |
2007-07-10 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
CA2481480C
(en)
*
|
2002-04-15 |
2011-04-12 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
CA2497628A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
FR2860235A1
(fr)
*
|
2003-09-29 |
2005-04-01 |
Yang Ji Chemical Company Ltd |
Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
|
EP1732549A4
(en)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
RS52741B
(en)
|
2004-11-05 |
2013-08-30 |
Janssen Pharmaceutica N.V. |
THERAPEUTIC USE OF FARNEZILTRANSPHERASE INHIBITORS AND PROCEDURES FOR MONITORING THEIR EFFICIENCY
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EP2545919A1
(en)
|
2005-12-23 |
2013-01-16 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
KR101367645B1
(ko)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
C-fms 키나제의 저해제로서의 복소환식 화합물
|
CA2649739C
(en)
|
2006-04-20 |
2015-09-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
EP2292663B1
(en)
|
2006-08-28 |
2013-10-02 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
KR101540823B1
(ko)
|
2007-03-30 |
2015-07-30 |
메디뮨 엘엘씨 |
항체 제제
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
RU2010121967A
(ru)
|
2007-10-31 |
2011-12-10 |
Медиммун, Ллк (Us) |
Белковые каркасные структуры
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
US9062076B2
(en)
*
|
2009-10-22 |
2015-06-23 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
US8541404B2
(en)
*
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
CN103328971B
(zh)
|
2010-07-28 |
2016-09-28 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
EP4063391A1
(en)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
US9741942B2
(en)
*
|
2012-10-11 |
2017-08-22 |
Merck Patent Gmbh |
Materials for organic electroluminescent devices
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
EP3041507B1
(en)
|
2013-08-26 |
2021-06-30 |
BioNTech Research and Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9856324B2
(en)
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
PL3800202T3
(pl)
|
2014-12-11 |
2023-06-12 |
Pierre Fabre Medicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
EP3265123B1
(en)
|
2015-03-03 |
2022-10-26 |
Kymab Limited |
Antibodies, uses & methods
|
TWI710642B
(zh)
|
2015-08-17 |
2020-11-21 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症病患之方法
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
CA3042747A1
(en)
|
2016-11-03 |
2018-05-11 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
JP7369038B2
(ja)
|
2017-05-31 |
2023-10-25 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにその治療的使用
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|